Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080946 · ClinicalTrials.gov registry record · Early Phase 1
Using Aspirin to Improve Immunological Features of Ovarian Tumors
A Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT05080946: Recruiting Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05080946 is a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 100 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05080946, a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma
Primary Outcome
Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells will be measured by using this formula: (density in the debulking surgery tissue sample - density in the biopsy tissue sample)\*100 / density in the biopsy tissue sample.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aspirin 325mg
Study Locations (4)
Virginia
- University of Virginia Comprehensive Cancer Center - Charlottesville
- Inova Schar Cancer Institute - Fairfax
Florida
- Moffitt Cancer Center - Tampa
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT05080946 shows while recruiting
NCT05080946 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05080946 reports a single indexed study location in Virginia, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT05080946 about?
NCT05080946 is a clinical study titled "Using Aspirin to Improve Immunological Features of Ovarian Tumors". The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma
What is the current status of trial NCT05080946?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2021-11-02. Estimated completion is 2026-12.
What conditions does trial NCT05080946 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT05080946?
The interventions under investigation include: Placebo (DRUG), Aspirin 325mg (DRUG).
Who is sponsoring clinical trial NCT05080946?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05080946 being conducted?
This trial has 4 study locations across Florida, Oregon, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05080946's enrollment target sits among peer trials
100 146th of 322 higher than 172 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
COMPLETED · Early Phase 1
-
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI